¹ **Gut resident** *Escherichia coli* **profile predicts the eighteen-**

² **month probability and antimicrobial susceptibility of urinary**

³ **tract infections.**

4 Veronika Tchesnokova¹, Lydia Larson¹, Irina Basova¹, Yulia Sledneva¹, Debarati

5 Choudhury¹, Thalia Solyanik¹, Jennifer Heng¹, Teresa Cristina Bonilla¹, Isaac

6 Pasumansky¹, Victoria Bowers¹, Sophia Pham¹, Lawrence T. Madziwa^{2,3}, Erika

- 7 Holden^{2,3}, Sara Y. Tartof^{4,5}, James D. Ralston^{2,3} and Evgeni V. Sokurenko^{1*}
- 8 ¹Department of Microbiology, University of Washington School of Medicine, 1705
- 9 NE Pacific St., Seattle, WA 98195, USA
- 10 ²Kaiser Permanente Washington, 2715 Naches Ave. SW, Renton, WA 98057, USA
- 11 ³Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Suite
- 12 1600, Seattle, WA 98101-1466, USA
- 13 ⁴Kaiser Permanente Southern California, Department of Research & Evaluation,
- 14 Pasadena, 100 S Los Robles, Pasadena, CA 91101, USA
- 15 ⁵Kaiser Permanente Bernard J. Tyson School of Medicine, Department of Health 16 Systems Science, 100 S Los Robles, Pasadena, CA 91101, USA
- 17

18 *** Corresponding author:** Evgeni V. Sokurenko, evs@u.washington.edu

- 19 **Short title:** Gut E. coli Profile Predicts 18-Month UTI Probability &
- 20 Antimicrobial Susceptibility

21 **Abstract**

22 **Background**: Community-acquired UTI is the most common bacterial infection 23 managed in general medical practice that can lead to life-threatening outcomes. 24 While UTIs are primarily caused by *Escherichia coli* colonizing the patient's gut, 25 it is unclear whether the gut resident *E. coli* profiles can predict the person's 26 risks for UTI and optimal antimicrobial treatments. Thus, we conducted an 27 eighteen-month long community-based observational study of fecal *E. coli* 28 colonization and UTI in women aged 50 years and above. 29 **Methods and Findings.** We enrolled a total of 1,804 women distributed among 30 age groups 50-59 yo (437 participants), 60-69 yo (632), 70-79 yo (532), and 31 above 80 yo (203), lacking antibiotic prescriptions for at least one year. The 32 provided fecal samples were plated for the presence of *E. coli* and other 33 enterobacteria resistant to trimethoprim/sulfamethoxazole (TMP/STX), 34 ciprofloxacin (CIP) and 3rd generation cephalosporins (3GC). *E. coli* was also 35 characterized as belonging to the pandemic multi-drug resistant clonal groups 36 ST131 (subclone H30) and ST1193. Following sample collection, the women 37 were monitored for 18 months for occurrence of UTI.

38 *E. coli* was cultured from 90.8% fecal samples, with 24.1% containing bacteria 39 resistant to TMP/STX, 19.4% to CIP, and 7.9% to 3GC. In 62.5% samples, only 40 all-susceptible *E. coli* were present. Overall, there were no age-related 41 differences in resistance prevalence. However, while the total *E. coli* H30 and

42 ST1193 carriage rates were similar (4.3% and 4.2%, respectively), there was a 43 notable increase of H30 carriage with age (P = .001), while carriage decreased 44 with age for ST1193 (P = .057).

45 Within 18 months, 184 women (10.2%) experienced at least one episode of UTI 46 - 10.9% among the gut *E. coli* carriers and 3.0% among the non-carriers 47 (P=.0013). The UTI risk among carriers of *E. coli* H30 but not ST1193 was 48 significantly above average (24.3%, P = .0004). The UTI probability increased 49 with age, occurring in 6.4% of 50-59 yo and 19.7% of 80+ yo (P<.001), with the 50 latter group being especially at high risk for UTI, if they were colonized by *E.* 51 *coli* H30 (40.0%, P<.001).

52 *E. coli* was identified in 88.1% of urine samples, with 16.1% resistant to 53 TMP/STX, 16.1% to CIP, 4.2% to 3GC and 73.1% to none of the antibiotics. 54 Among tested urinary *E. coli* resistant to antibiotics, 86.1% matched the 55 resistance profile of *E. coli* in the fecal samples, with the clonotyping and whole 56 genome sequencing confirming the matching strains' identity. Positive predictive 57 value (PPV) of using gut resistance profiles to predict UTI pathogens' 58 susceptibility to TMP/STX, CIP, 3GC and all three antibiotics were 98.4%, 59 98.3%, 96.6% and 95.3%, respectively. Corresponding negative predictive 60 values (NPV) were 63.0%, 54.8%, 44.4% and 75.8%, respectively. The AUC 61 ROC curve values for the accuracy of fecal diagnostic testing for the prediction 62 of UTI resistance ranged .86-.89. The fecal test-guided drug-bug mismatch rate

- 63 for empirical (pre-culture) prescription of TMP-SXT or CIP is reduced to \leq 2% in
- 64 89.6% of patients and 94.8% of patients with an optional 3GC prescription.
- 65 *Conclusion*. The resistance profile and clonal identity of gut colonizing *E. coli*,
- 66 along with the carrier's age, can inform personalized prediction of a patients'
- 67 UTI risk and the UTI pathogen's antibiotic susceptibility within an 18-month
- 68 period.

69 **Introduction**

70 The personalized or precision medicine approach is based on defining the 71 potential risks, expected outcomes, and optimal treatment of diseases based on 72 an individual's unique biomarkers, which are usually genetically determined but 73 can also depend on and behavioral factors [1]. The indigenous microbiota that 74 colonizes the gut, vagina or other body compartments is considered an integral 75 component of the human organism, influencing various aspects of individuals' 76 health (for review see [2, 3]). At the same time, the resident microflora serves 77 as a major source of opportunistic bacterial pathogens for the host, including 78 those resistant to multiple antibiotics [4-6]. However, it remains unclear how the 79 identification of certain bacterial species and/or sub-species lineages in the 80 colonizing microbiota can predict the person's risks for developing specific 81 clinical infections or guide antibiotic treatment choices, especially in the era of 82 continuously increasing antimicrobial resistance.

83 Gut resident microbiota, *Escherichia coli* and other enterobacterial species in 84 particular, is the main reservoir for strains causing the most common bacterial 85 infection treated by general practitioners - community-acquired urinary tract 86 infections (UTIs) with the estimated total annual incidence rate of up to 7% the 87 USA and globally [7-10]. Postmenopausal women, typically aged 50 or older, 88 face a particularly high risk of developing severe and drug-resistant forms of 89 UTIs [11, 12]. While acute uncomplicated cystitis is the most common form of 90 UTI, its very high incidence places a substantial financial burden on the

91 healthcare system, especially if the initial treatment choice was not effective 92 [10, 13]. Also, more severe UTI forms such as recurrent cystitis, pyelonephritis, 93 or urosepsis (an estimated one-third of sepsis cases begin as UTIs) significantly 94 contribute to the overall costs associated with UTIs, particularly in elderly [10, 95 13, 14].

96 UTIs are almost exclusively treated with antibiotics, thus representing a primary 97 single reason for antibiotic use in humans [15]. However, antimicrobial 98 resistance has reached pandemic proportions in the last few decades, 99 contributing to increased mortality rates and healthcare costs (estimated at 100 approximately \$2,000 per ineffective prescription) [16-19]. Because determining 101 the resistance profiles of infecting bacteria takes 2-3 days, physicians must 102 resort to the empirical (pre-culture) choice of antibiotics. Typically, empirical 103 treatment is inherently imprecise as it is not informed by the specific resistance 104 profile of infecting bacteria but relies on general resistance patterns in the local 105 community [20]. For empiric treatment of uncomplicated UTI, the Infectious 106 Diseases Society of America (IDSA) recommends treatment with an antibiotic if 107 the local resistance prevalence in *E. coli* is no more than 20%, whereas for 108 pyelonephritis or other severe forms, the recommended resistance prevalence 109 should be <10% [20-22]. Unfortunately, the resistance to commonly used 110 antibiotics is now often well above 20% and the empiric guesswork results in the 111 prescription of ineffective antibiotics ('drug-bug mismatches') in 15-35% of 112 cases, leading to increased health care cost and overuse of last-line, broad-113 spectrum antimicrobials [16, 18, 19].

114 It has been well-established that extraintestinal pathogenic *E. coli* and other 115 enterobacteria causing UTIs derive from the gut, where they reside as part of 116 the commensal microbiota, typically existing as a consortium of multiple strains 117 (for review see [23]). These commensals include *E. coli* strains resistant to 118 antibiotics, and their presence in the gut may not be contingent upon antibiotic 119 use by the individual [24-28]. Among the antibiotic resistant *E. coli* causing 120 UTIs, strains of two multi-drug resistant clonal groups (genetic families) 121 dominate in the USA and globally – one is the sequence types ST131-H30R/Rx 122 (aka ST131 clade C1/C2; *E. coli* H30 for further) and ST1193 [24, 25, 27, 29- 123 33]. Their rampant spread was noted in the first and second decades of this 124 century, respectively, with fluoroquinolone resistance being the signature of 125 both clonal groups. It has been hypothesized that the high prevalence and 126 global spread of *E. coli* H30 and ST1193 could be connected to their success as 127 gut colonizers [25, 34-36].

128 Multiple studies have estimated the risks of extraintestinal infections associated 129 with gut carriage of multi-drug resistant *E. coli*. Generally, these studies have 130 focused on the risks of bacteremia and included samples from hospital/ICU-131 admitted patients and/or those who underwent various organ transplant 132 procedures [37-40]. The correlation between gut carriage and consequent drug-133 resistant infections has been sufficiently strong to motivate studies on gut 134 decolonization of patients at risk, employing methods such as fecal microbiome 135 transplantation, probiotics, and/or phage therapies [37, 41-44]. To our 136 knowledge, however, there have been no observational prospective studies to

137 assess the value of characterizing gut-colonizing bacteria for predicting the 138 risks and guiding the antimicrobial treatment of such a vastly common antibiotic-139 treated medical condition as UTI. Additionally, while it is well-known that certain 140 risk groups for UTI exist, such as patients with diabetes, postmenopausal 141 women or, the elderly [45-47], it is unclear to what extent the probability of UTI 142 in those groups are also defined by the species or clonal type of gut-colonizing 143 enterobacteria.

144 Here, we present the outcomes of an 18-month prospective observational study 145 on the risk for UTI women above 50 yo and the correlation between the clonal 146 and resistance profiles of *E. coli* in pre-collected fecal samples and those 147 isolated from the follow-up clinical urine samples. The study group included 148 1,804 women receiving out-patient care in the Kaiser Permanente system in 149 Washington State, USA (KPWA), serving mostly the metropolitan Seattle/Puget 150 Sound Area, who had not received any antibiotics for at least one year before 151 providing the fecal sample. We demonstrate that the UTI risk, while dependent 152 on age, varied considerably based on the clonal identity of gut-colonizing *E.* 153 *coli*. Additionally, determining the resistance profile of gut *E. coli* significantly 154 improves the accuracy of resistance prediction for UTI-causing strains against 155 three commonly used antibiotics: trimethoprim/sulfamethoxazole (TMP/STX), 156 ciprofloxacin (CIP), and 3rd generation cephalosporins (3GC). Thus, we believe 157 that the analysis of gut microbiota for the presence, resistance profile, and 158 clonal identity of resident *E. coli* shows potential for a personalized medicine 159 approach in the clinical management of UTI, empowering antimicrobial

160 stewardship efforts and, potentially, developing effective means for infection 161 prevention.

162 **Methods**

163 *Study design and participants*. This prospective cohort study from May 1, 164 2021 through December 31, 2021 was conducted among women aged 50 years 165 and older enrolled in Kaiser Permanente Washington (KPWA). One-year 166 membership prior to enrollment was required to clinical and demographic data 167 prior to baseline. Besides enrollment, age and gender, exclusion criteria 168 included any antibiotic prescription, UTI and placement in a long-term care 169 facility within a year prior to enrollment in the study. This study was approved 170 by the KPWA) Research Institute Institutional Review Board. The procedural 171 details pertaining to the mailing of study kits to participants are described in the 172 previous manuscript [24].

173 *Processing of fecal samples and typing of fecal E. coli* was described in 174 detail previously [24]. Briefly, fecal samples were plated on either pre-poured 175 HardyCHROM™ UTI agar plates (Hardy Diagnostic, USA) or plates prepared 176 from HiChromeTM UTI Agar (HiMedia Laboratories Pvt, Ltd.) supplemented with 177 ciprofloxacin (CIP, 0.5 mg/L), trimethoprim/sulfamethoxazole (TS, 4/76 mg/L), 178 ceftazidime (CAZ, 8 mg/L), ceftriaxone (CTX, 2 mg/L). Plates were incubated 179 16-20h at 37°C, and single colonies (SCs) morphologically identified as 180 potential *E. coli* were cultured, saved and tested further for (a) resistance to

181 CIP, TMP/STX and 3rd generation cephalosporins (3GC – CAZ and CTX), (b) 182 clonality based on sequencing of four loci – *fumC*, *fimH*, *gyrA* and *parC*, as 183 described previously [24].

184 *Processing of clinical urine samples and typing of urine E. coli*. If a study 185 participant submitted a urine sample to KPWA clinical laboratory, a routine 186 urinalysis test was performed, followed by culture and sensitivity testing if 187 required. Starting February 2022, the UW laboratory was provided an aliquot of 188 the urine sample, which was processed using the same protocol as fecal sample 189 described above, adding *E. coli* clonality where applicable to sample 190 information.

191 *UTI identification*. The incidence of urinary tract infections in study

192 participants was deduced from their electronic health records (EHRs).

193 Records were examined once all participants had surpassed 18 months

194 following the submission of the fecal sample. UTI was characterized based

195 on the criteria outlined in Bruxvoort et al [7], including UTI diagnosis codes,

196 antibiotic prescriptions, urinalysis test results, and culture findings.

197 *Resistant E. coli isolates comparison using whole genome sequencing.*

198 Whole genome sequencing was conducted using the Illumina MiSeq platform

199 following the manufacturer's guidelines. Genomic DNA libraries were

200 prepared using the Nextera XT Library Prep Kit (Illumina, CA). Raw data

201 were uploaded to the Enterobase database

202 (https://enterobase.warwick.ac.uk/) for genome assembly and allele calling

203 processes. Core gene sequences were utilized to assess the phylogenetic 204 relationship among isolates within the same clones.

205 *Search for sensitive E. coli clones within fecal samples.* Fecal samples 206 were examined to identify the presence of the *E. coli* clone responsible for 207 UTI in the participant. Three methods were employed. Firstly, a minimum of 208 two individual single colonies were isolated directly from the sample during 209 initial processing. These colonies were then screened for resistance profiles 210 and clonal identity. If these isolated colonies did not match the 211 uropathogenic *E. coli* clone, further isolation and screening of 9-28 212 (averaging 13) individual colonies were conducted. Secondly, the 213 uropathogenic *E. coli* strains were subjected to testing for resistance against 214 a broader spectrum of antibiotics, including ampicillin (50 and 100 mg/L), 215 rifampin (2 and 4 mg/L), tetracycline (16 mg/L), cefazoline (4 and 8 mg/L), 216 chloramphenicol (16 and 32 mg/L), kanamycin (12.5 and 25 mg/L), 217 gentamicin (15 mg/L), spectinomycin (15 mg/L), streptomycin (50 mg/L), 218 trimethoprim (8 and 16 mg/L), and sulfamethoxazole (80 and 160 mg/L). 219 Subsequently, fecal samples were plated on the antibiotic of interest to 220 search for isolates exhibiting the same resistance profile. Thirdly, fecal 221 samples were resuspended in phosphate-buffered saline (PBS) and between 222 -10⁴ cfu/plate were cultured on McConkey agar. Plates were divided into 223 sectors, and bacteria from each sector were collected and re-suspended in 1 224 mL PBS. A 100 uL aliquot of this suspension was used for DNA purification 225 using 5% Chelex 100 (Bio-Rad, Richmond, CA) [48]. The purified DNA was

226 then subjected to qPCR to detect the presence of urinary clone-specific loci 227 and/or SNPs. In the event of a positive reaction, the saved bacterial 228 suspension was plated again to obtain and test individual single colonies.

229 *Whole genome sequencing*. Matching sets of *E. coli isolates* from clinical 230 urine samples and predating fecal samples underwent sequencing on 231 Illumina MiSeq platform using MiSeq 600 cycle v3 kit (Illumina). Raw reads 232 were uploaded to Enterobase database (<https://enterobase.warwick.ac.uk/>) 233 where they were assembled. The core genes were then downloaded from 234 Enterobase and analyzed for sequence identity. The trees were bult using 235 MEGA v7 software. Enterobase uberstrain names are listed in Table S3.

236 *Statistical analysis*. Chi-square test was used to evaluate 2x2 comparisons. 237 Logistic regression was used to analyze the prevalence of different *E. coli* 238 strains and the incidence of UTI among participants across different age 239 groups. The analysis was conducted using STATA 14.2 Software (StataCorp, 240 Texas, USA).

241 **Results**

242 *Antibiotic resistant E. coli are carried at high rates by women without*

243 *recent exposure to antibiotics.* We collected fecal samples from 1,804 women 244 of age 50 years or above who did not take antibiotics for at least one year prior 245 to enrollment. Among the enrollees, 437 women (24%) were of age 50-59, 632

246 (35%) aged 60-69, 532 (30%) aged 70-79 and 203 (11%) aged 80 and above 247 (Table 1) (Fig S1A).

248 As expected, *E. coli* was present in a vast majority of the fecal samples (90.8% 249 on average) across all age groups, with a slight but statistically significant 250 decreased *E. coli* carriage observed for younger enrollees (Table 1) (Fig S1B). 251 The *E. coli* positive samples were tested for the presence of any resistance to 252 TMP/STX, CIP and 3GC. In 62.5% samples, all *E. coli* were sensitive to all three 253 antibiotics, 24.1% samples contained *E. coli* resistant to TMP/STX: 19.4% to 254 CIP and 7.9% to 3GC (Table 1), with 10.8% having *E. coli* resistant to more than 255 one antibiotic. There were no differences between the age groups in prevalence 256 of samples with resistant *E. coli* (Table 1) (Fig S1C-E).

257 Among the *E. coli*-positive fecal samples, clonal groups *E. coli* H30 and ST1193 258 were found among 4.3% and 4.2%, respectively, with a combined prevalence of 259 43.4% among the samples with CIP-resistant *E. coli*. The gut carriage of *E. coli* 260 H30 significantly increased with age (P = .001), ranging from 2.3% in the 50-59 261 yo group to 7.9% in women of 80+ yo (Table 1) (Fig S1F), while an opposite 262 age-dependence tendency was observed for the carriage of ST1193, with 5.2% 263 in the youngest group but only 2.1% ($P = .057$) in the elder group (Table 1) (Fig 264 S1G).

265 Thus, a third (34.1%) of women 50 yo and older without recent exposure to 266 antibiotics carry gut *E. coli* that is resistant to at least one of the three 267 commonly used antibiotics, with no overall differences in the resistant *E. coli* 268 carriage between different age groups. At the same time, the older women 269 tended to carry significantly more frequently *E. coli* from the multi-drug resistant 270 clonal group ST131-H30.

271 *The 18-month probability of UTI occurrence depends on E. coli* **presence**

272 **and clonality**. During the follow up 18 months of observation, 5-17 enrollees

273 per month were diagnosed with UTI (Fig S2), with a total 184 women (10.2%)

274 having at least one episode of UTI (Table 2). All urines were collected from

275 women as outpatients; thus, all UTI cases qualify as being community acquired.

276 The frequency of UTI cases significantly increased with age (Fig S1H),

277 occurring in 1 in 5 (19.7%) women of age 80+ (Table 2). Interestingly, across

278 the age groups UTI occurred nearly four-fold more frequently among women

279 who carried *E. coli* in the gut than in those with no *E. coli* presence in feces.

280 In the total cohort of enrollees, the 18-month rate of UTI did not significantly 281 differ between the carriers of all-sensitive *E. coli* and those carrying *E. coli* 282 resistant to any of the tested antibiotics (Table 2). In contrast, the rate of UTI 283 was nearly significantly higher than average for the carriers of multi-drug 284 resistant *E. coli* H30 (24.3%; p=.0004). Notably, the rate of UTI among the 285 carriers of ST1193 was at the average level.

286 When analyzed by age groups, the rates of UTI increased with age among the 287 carriers of all-sensitive, TMP/STX-resistant, and CIP-resistant *E. coli* but the 288 increase with age did not reach the statistical difference across the 3GC 289 carriers (Fig S1I-M). While the UTI rates did not change with age among the

290 carriers of ST1193, the UTI rates increased with age among the *E. coli* H30 291 carriers, reaching the 18-month occurrence of 36.4% in women or age 70-79 292 and 40.0% of age 80+. Moreover, in the two elder groups of enrollees, the UTI 293 probability for the *E. coli* H30 carriers was significantly higher than for carriers 294 of any other *E. coli*.

295 Thus, nearly 1 in 8 of women aged 50 and above, who are not taking antibiotics 296 but carry *E. coli* in their gut, would experience a UTI within an 18-month period. 297 In the older women, however, the overall UTI frequency increases up to two-fold 298 overall and nearly four-fold in those who are colonized with the multi-drug 299 resistant *E. coli* H30.

300 *E. coli is the predominant and most resistant urinary pathogen*. To 301 evaluate the identity and resistance profiles of urinary pathogens we analyzed a 302 total of 134 bacteriology-positive urine samples submitted by our study 303 enrollees to the clinical laboratory as part of the initial UTI diagnostics. The 304 bacteriology-positive samples were evenly spread across the 18 months of 305 observation (Fig S2). *E. coli* was identified in 118 (88.1%) of the samples and 306 was predominant at a similarly high level across all ages. Out of the remaining 307 16 samples, more than half (9 samples) contained *Klebsiella* spp., with the rest 308 having *Citrobacter* spp. (in 2 samples), *P. mirabilis* (3), *Salmonella enterica* (1) 309 and *E. faecalis* (1). Among the urine-isolated *E. coli*, 82 (69.5%) isolates were 310 sensitive to all three antibiotics, 19 (16.1%) were resistant to TMP/STX, 19 311 (16.1%) to CIP and 5 (4.2%) to 3GC (Table 3), with 6 (4.6%) resistant to

312 multiple antibiotics (Table S1). Among the non- *E. coli* urinary pathogens, none 313 were resistant to any of the tested antibiotics, which is significantly lower 314 (p=.008) than the proportion of resistant *E. coli* among the clinical isolates 315 (Table S2).

316 Thus, in the community-acquired UTI among the women aged 50 and above, *E.* 317 *coli* is both the predominant pathogen and responsible for most of the antibiotic-318 resistant infections.

319 *Resistance profile of E. coli in the urine samples match those in fecal* 320 *samples due to the strains' identity*. Baseline fecal *E. coli* was available from 321 all 118 enrollees with *E. coli* positive UTIs. Among the fecal samples, 64.2% 322 contained all-sensitive gut *E. coli*, 20.3% contained *E. coli* resistant to 323 TMP/STX, 23.3% to CIP and 6.8% to 3GC. There was a highly significant (P < 324 .001) overlap between the presence of resistant *E. coli* in urine and the 325 corresponding fecal samples – out of 36 urine isolates resistant to any of the 326 three antibiotics, 31 (86.1%) had an *E. coli* with the same resistance pattern in 327 the corresponding fecal samples. Among them, 89.5% of urine isolates had an 328 *E. coli* with a matching resistance to either TMP/STX or FQ and 80% for the 329 resistance to 3GC (Table 3). Similarly, in 83.7% cases when the urine *E. coli* 330 was sensitive to all three antibiotics, there was no resistant *E. coli* in the 331 corresponding fecal sample.

332 The high-level correspondence between the resistance phenotypes of fecal and 333 urinary samples obtained within 18 months of each other suggests that the

334 same *E. coli* strain is present in both sample types. Indeed, in 21 cases when 335 both fecal and urine sample were available for genetic clonotyping and 336 contained isolates resistant to the same antibiotic(s), all of them were of the 337 same clonal sub-group (Table S1). We compared 9 pairs of such clonally 338 matching strains by whole genome sequencing and confirmed that the same-339 person urine and fecal samples are much closer genetically to one another than 340 other strain pairs even of the same clonotype (Fig S3).

341 Five sample pairs with mismatched resistance profiles between fecal and UTI 342 isolates were evenly spread across the 18 months of observation, obtained at 343 months 4, 6, 13, 16 and 17 (Table S1). Out of those, 3 samples were available 344 for the clonal identity, with all determined to be of a different nature.

345 Thus, there is a high correspondence between the resistance profiles of gut 346 resident *E. coli* and UTI isolates obtained from the same person within 18 347 months from fecal sample.

348 *Urinary E. coli prediction based on fecal E. coli antibiotic resistance*

349 *(FECAR) testing*. Because only a small portion of *E. coli* from urine samples did 350 not have a fecal *E. coli* with a matching resistance profile, positive predictive 351 values (PPV) for the susceptibility to antibiotics ranged between 94.5% for the 352 all-sensitive urine isolates to 99.1% for those sensitive to 3GC (Table 4). The 353 negative predictive values (NPV; prediction of non-susceptibility) ranged 354 between 71.1% for any of the three antibiotics and 44.4% for 3GC. Notably, 355 PPV and NPV remained at similar levels for the resistance prediction for the

356 entire set of 134 urinary pathogens (i.e. including the 16 urine samples with 357 non- *E. coli* bacteria, all of which as indicated above, were sensitive to the three 358 antibiotics), because vast majority of the corresponding fecal samples had only 359 all-sensitive *E. coli* (Table 4; Table S2). We estimated the diagnostic value of a 360 potential fecal *E. coli* antibiotic resistance (FECAR) test to determine the 361 resistance of UTI-causing pathogens in our cohort. The values of AUC (Area 362 Under the Receiver Operating Characteristic (ROC) Curve) for the FECAR test 363 ranged from .86-.89, i.e., at the 'excellent' level [49].

364 We analyzed how, hypothetically, the FECAR testing could improve the 365 accuracy of empirical (pre-culture) treatment of the UTI cases in our study 366 population by guiding the antibiotics choice. Using FECAR testing, TMP/STX, 367 CIP and 3GC would be '*recommended'* for use in nearly 78%, 76% and 93% of 368 all UTI cases, respectively, based on the absence of resistant *E. coli* in the 369 corresponding fecal samples (Table 5). The FECAR-guided antimicrobial choice 370 would lead to a drug-bug mismatch in only 1.9%, 2.0% and 0.8% of cases, 371 respectively. Either TMP/STX or CIP would be recommended in almost 90% 372 case and at least one of the antibiotics in 95% cases (Table 5).

373 Based on the 2022 annual antibiogram of *E. coli* isolated in the clinical 374 microbiology laboratory of all KPWA enrollees, the local resistance to all three 375 antibiotics is \leq 20% - 16.9% to TMP/STX, 12.8% to CIP, and 5.8% to 3GCR. 376 Thus, any of them can be recommended for the UTI treatment in our enrollees, 377 assuming all patients had an uncomplicated cystitis. In our cohort, however,

378 such FECAR-unguided treatment would lead to a drug-bug mismatch in 14.2% 379 for TMP/STX and CIP, which is significantly higher than the mismatch resulted 380 from the FECAR guidance ($P = 0.0009$ and $P = 0.0011$, respectively). For the 381 unguided 3GC treatment the mismatch would occur in 3.7% of cases, which is 382 not significantly higher (P = .0963).

383 In contrast, the use of TMP/STX, CIP and 3GC would be *'not recommended*' by 384 FECAR in 21.6%, 23.9% and 6.8%, respectively, due to the presence of 385 resistant *E. coli* in feces. While in 41.4, 46.9 and 55.6%, respectively, of the 386 corresponding UTI cases, the isolate happened to be susceptible to the 387 antibiotic, the antibiotics use in the not recommended cases would result in 388 drug-bug mismatch rate that is significantly above the mismatch rates resulted 389 from the unguided treatment, well exceeding the 20% rates considered to be 390 acceptable by the IDSA recommendations.

391 **Discussion**

392 Our study demonstrates that the presence and clonal identity of gut *E. coli* 393 contribute to the risk of UTI. Moreover, although the human gut is often 394 colonized by multiple strains of *E. coli* simultaneously (as discussed in detail 395 below), the presence/absence of gut *E. coli* resistant to commonly used 396 antibiotics could be used for predictive diagnostics of urinary pathogen 397 susceptibility, within 18 months of the fecal testing and with an 'excellent level' 398 of test accuracy. Thus, such testing can support a personalized medicine

399 approach to UTI management by improving prediction of UTI infection and 400 tailoring the empiric treatment choice.

401 Although the time of reaching menopause varies widely, women aged 50 and 402 above are generally considered to be in the range of premenopausal to post-403 menopausal. Due to estrogen decline, a rise in vaginal pH, higher urine 404 retention in the bladder, and other factors, postmenopausal women are known 405 to be at an increased risk for severe, complicated, and drug-resistant forms of 406 UTI [50, 51]. All women selected for the study did not have exposure to 407 antibiotics and were not diagnosed with UTI or hospitalized for any reason at 408 least one year prior to the study enrollment. Although these criteria may result 409 in a study population with lower risk compared to a general population women 410 50 years and older, this would rather result in an underestimate of the potential 411 impact of FECAR, which could be expected to have an even higher impact in a 412 population with more frequent infection and therefore higher probability of 413 resistance.

414 As expected, *E. coli* was isolated from the fecal sample of most women. Though 415 a clear minority, *E. coli* non-carriers were ~2-times more common among 416 women younger than 70. This is a novel finding, the underlying reason for which 417 remains unclear. Also novel is the follow-up observation that *E. coli* non-carriers 418 are about three times less likely to have UTIs than carriers, strongly suggesting 419 that *E. coli* is the major causative species for UTI. These data provide further

420 support that the probability of UTI depends on and, thus, may be predicted by 421 the presence or absence of gut-colonizing *E. coli*.

422 We concentrated here on three antibiotics commonly used for the CA-UTI 423 treatment. TMP/SMX (Bactrim) is suggested as the first line antibiotic for 424 uncomplicated UTI, similar to nitrofurantoin or fosfomycin [52]. CIP is suggested 425 as an alternative drug of choice when the first line antibiotics cannot be used for 426 any reason, or as the first-choice antibiotic if pyelonephritis is suspected, 427 usually combined with a single-dose boost of parenteral 3GC. However, as 428 mentioned in the Introduction, the empirical use of antibiotics is recommended 429 for the treatment of cystitis only if the local resistance prevalence is below 20%, 430 or below 10% for the treatment of pyelonephritis [21].

431 Surprisingly, even though study participants did not take antibiotics for at least 432 a year prior enrollment, just over a third of them carried gut *E. coli* resistant to 433 one or more of the three antibiotics. Interestingly, the carriage of resistant *E.* 434 *coli* did not differ significantly between age groups, in accordance with a lack of 435 evidence that increased age is a risk factor for carriage of drug-resistant 436 bacteria [28]. However, the lack of association could because our study enrolled 437 only women who had not taken antibiotics in the year prior.

438 The most striking difference between the age groups was found in the carriage 439 of *E. coli* belonging to the pandemic multi-drug resistant clonal groups *E. coli* 440 H30 and ST1193. *E. coli* H30 is estimated to have emerged in the 1990s gained 441 notoriety as the main cause of antibiotic resistant UTIs globally since early

442 2000s [33, 53]. Independently of resistance, it is also associated with 443 complicated and severe forms of UTIs, such as recurrent cystitis, pyelonephritis, 444 urosepsis, and infections in diabetic and immunocompromised patients [54]. 445 ST1193 emerged later than *E. coli* H30 but started to challenge the latter in 446 global UTI predominance in the mid-late 2010s [29, 31]. It has been proposed 447 that the phenomenal global spread of both *E. coli* H30 and ST1193 is 448 associated with their success as gut colonizers, possibly connected to the 449 mutations responsible for CIP resistance [35, 36]. The fact that *E. coli* H30 is 450 significantly more commonly carried by older women corresponds to our 451 previous findings in a smaller prior study [11].

452 The underlying reason for the age differences in *E. coli* H30 and ST1193 453 carriage is not yet known. However, we believe that this observation suggests 454 that resistance *per se* might not be the main selective factor for gut colonization 455 and other host factors, e.g., immune status, may be in play. Whatever the 456 underlying reason for the different carriage rates it's important for predicting the 457 occurrence of UTI. The overall 18-month incidence of UTIs in *E. coli* H30 458 carriers was twice as high as the average – 1 in 5 women. This was due to an 459 astoundingly high rate of *E. coli* H30 UTIs in women aged 70+, occurring in 460 more than a third of the enrollees, higher than in almost every other category of 461 *E. coli* carriers of this age. Interestingly, the UTI rates for ST1193 carriers were 462 not different from the average, potentially reflecting differences either in the 463 urovirulence potential of the strains or in the host defense status of the 464 colonized populations.

465 The significantly higher rate of UTIs for *E. coli* H30 illustrates the importance of 466 predicting UTI based on the clonal identity of the resident strain, in combination 467 with considering host demographics. While we did not examine the UTI 468 incidence for other major clonal groups of *E. coli*, this finding highlights the 469 value of examining the microbiota composition beyond large taxonomic groups 470 or even species (as mostly done by microbiome studies) but at the sub-species, 471 clonal group level that we propose to term as a 'clonobiome' analysis [55]. As 472 with most human pathogens, the *E. coli* species is clonal by nature, with the 473 majority of strains belonging to a relatively limited number of genetically well-474 defined and closely related clonal groups (i.e., Sequence Types or STs) that 475 can significantly differ from each other in virulence potential and/or antimicrobial 476 resistance profiles [56, 57]. Thus, by defining the clonal diversity of the 477 colonizing strains, the clonobiome approach allows us to assess more 478 accurately the clinical risks and treatment options associated with the resident 479 microbiota. To note, it was shown that the clonal identity of multiple gut-480 colonizing *E. coli* strains can be directly determined in fecal samples by deep 481 sequencing of just two genetic loci – *fumC* and *fimH* (CH typing) [55].

482 While predicting the probability of UTI in certain risk groups could be of 483 practical interest, we believe that, if a clinical infection develops, it is even more 484 important to accurately predict the antibiotic susceptibility of the pathogen. We 485 demonstrate here that, within up to 18 months of fecal sample analysis, the 486 resistance of the gut resident *E. coli* – dubbed here as FECAR test - served as 487 a valuable predictive tool for estimating the susceptibility of the UTI-causing

488 bacteria for the three tested antibiotics. Though this conclusion is based on the 489 limited testing and data we have for our population in the study, the significant 490 improvement in the potential antibiotic choice is reflected by the 'excellent' 491 discrimination level of FECAR for the resistance to TMP/STX, CIP and 3GC 492 based on the AUC values between 0.8 and 0.9 [49]. Due to the relatively low 493 overall resistance to third-generation cephalosporins (3GC), the reduction in 494 drug-bug mismatch rates in the allowed cases was not as obvious as with 495 TMP/STX and CIP, but the AUC value was also at the excellent level. Moreover, 496 because *E. coli* was responsible for nearly 90% of CA-UTI cases, the diagnostic 497 prediction was also excellent for all UTI cases overall. Thus, the accuracy of 498 predicting resistance profiles of UTI-causing *E. coli* based on the fecal sample 499 collected within 18 months is sufficiently high to warrant further studies to 500 develop this approach as a predictive tool for antibiotic selection in UTI. The 501 FECAR-guided empirical choice of antibiotics could lead to a several-fold 502 reduction of the drug-bug mismatches relatively to the unguided treatment.

503 Naturally, the correlation between the resistance profiles of gut *E. coli* and that 504 of urine *E. coli* suggests that the strains causing UTIs derived from the gut 505 colonizers. Indeed, clonal identity was established between the vast majority of 506 fecal and urine strains with matching resistance profiles when they were 507 obtained from the same individual. In our study, strain clonality was determined 508 by a highly discriminatory sub-ST genotyping method [58, 59], strongly implying 509 the identity of the strains that was confirmed by whole genome sequencing of 510 representative strain pairs.

511 Previous studies varied significantly in their estimates of the duration of gut 512 colonization by specific *E. coli* strains – ranging from several days to a few 513 years, with a possible existence of 'transient' colonizers with a short-lived gut 514 residence span and long-term 'resident' colonizers with a much slower turnover 515 [60]. Though our study did not analyze the duration of gut colonization per se, it 516 suggests that uropathogenic antibiotic-resistant strains can reside in the gut for 517 a relatively long time, making the 18-month predictability of the urinary 518 pathogen feasible. This corresponds to previous studies suggesting that *E. coli* 519 H30 and ST1193 strains may be well-adapted as colonizers [12, 34, 35, 61]. 520 Moreover, it has been proposed that the genetic factors contributing to gut 521 colonization could serve as evolutionary pre-adapted (coincidental) urovirulence 522 factors [62, 63]. Finally, our results support the hypotheses that persistent gut 523 colonization by antibiotic-resistant *E. coli* may not necessarily depend on an 524 antibiotic use by the host [26].

525 The human gut is usually colonized by multiple strains of *E. coli* simultaneously. 526 For example, it has been shown that *E. coli* H30 in the gut is found, on average, 527 with 1-2 other strains, often exhibiting different resistance profiles and in 528 different relative proportions. While in the current study, the genetic diversity of 529 gut resident *E. coli* was not analyzed, colonization by multiple strains is 530 expected for most enrollees. For example, the fact that in certain carriers of 531 resistant strains, UTIs were caused by sensitive strains could be due, at least in 532 some cases, to the possibility that resistant strains were co-colonizing the gut 533 with a sensitive strain that eventually caused the infection. Alternatively, this

534 could have happened because the resistant strain found originally in the fecal 535 sample was replaced by the sensitive strain as part of the strains' turnover. Gut 536 strains dynamics could also explain the fact that, in a small number of cases, 537 UTI was caused by a resistant strain not found in the fecal sample, which could 538 be acquired by the host after the original sample collection. This, however, 539 should be resolved in future studies.

540 It remains to be determined whether a more detailed exploration of gut *E. coli* 541 strains' diversity, fecal abundance, the presence/absence of putative virulence 542 factors, and different resistance genes could further improve the prediction of 543 the UTI risks and optimal treatment. In addition to validating our results, future 544 studies should also assess whether FECAR could be used for prediction of the 545 UTI pathogens resistance to a broader spectrum of antibiotics. Furthermore, the 546 strain-dependent UTI risks need to be delineated across various age groups and 547 genders, considering additional host factors such as co-morbidities,

548 immunodeficiency status, etc. Despite the limitations of our study and remaining 549 questions, we strongly believe that discerning gut *E. coli* profiles should become 550 an integral component of the personalized medicine approach in UTI 551 management. Additionally, our findings should prompt further research in the 552 development of innovative strategies to prevent UTIs by, for example, 553 selectively decolonizing gut carriers ofhighly urovirulent and/or multi-drug 554 resistant enterobacterial strains. This may not only diminish risks for severe 555 complications in the most vulnerable individuals but also contributes to curbing

- 556 the antimicrobial resistance pandemic by reducing the transmission and
- 557 community circulation of these pathogens.

558 **Acknowledgments**

- 559 This work was supported by the National Institutes of Health R01AI106007 and
- 560 R01AI150152 to EVS.

561 **References**

- 562 1. NIH. PERSONALIZED MEDICINE. Available at:
- 563<https://www.genome.gov/genetics-glossary/Personalized-Medicine>. 564 Accessed 2/23/2024.
- 565 2. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut 566 microbiota on human health: an integrative view. Cell **2012**; 148(6): 567 1258-70.
- 568 3. Wilson M. The Human Microbiota in Health and Disease: An Ecological 569 and Community-based Approach. 1st Edition ed. New York: Taylor & 570 Francis group, **2018**.
- 571 4. Donskey CJ. The role of the intestinal tract as a reservoir and source 572 for transmission of nosocomial pathogens. Clin Infect Dis **2004**; 39(2): 573 219-26.

649 fluoroquinolone resistant *Escherichia coli* clone ST1193 emerged via

673 37. Campos-Madueno EI, Moradi M, Eddoubaji Y, et al. Intestinal

- 674 colonization with multidrug-resistant Enterobacterales: screening,
- 675 epidemiology, clinical impact, and strategies to decolonize carriers. Eur
- 676 J Clin Microbiol Infect Dis **2023**; 42(3): 229-54.

677 38. Denkel LA, Maechler F, Schwab F, et al. Infections caused by

678 extended-spectrum beta-lactamase-producing Enterobacterales after

679 rectal colonization with ESBL-producing *Escherichia coli* or *Klebsiella*

680 *pneumoniae*. Clin Microbiol Infect **2020**; 26(8): 1046-51.

681 39. Magruder M, Sholi AN, Gong C, et al. Gut uropathogen abundance is a

682 risk factor for development of bacteriuria and urinary tract infection.

683 Nat Commun **2019**; 10(1): 5521.

684 40. Grasselli G, Scaravilli V, Alagna L, et al. Gastrointestinal colonization

685 with multidrug-resistant Gram-negative bacteria during extracorporeal

686 membrane oxygenation: effect on the risk of subsequent infections and

687 impact on patient outcome. Ann Intensive Care **2019**; 9(1): 141.

- 710 48. Yang JL, Wang MS, Cheng AC, Pan KC, Li CF, Deng SX. A simple and 711 rapid method for extracting bacterial DNA from intestinal microflora for
-

712 ERIC-PCR detection. World J Gastroenterol **2008**; 14(18): 2872-6.

- 713 49. Hosmer D, Lemeshow, S. Applied Logistic Regression, **2000**.
- 714 50. Raz R, Gennesin Y, Wasser J, et al. Recurrent urinary tract infections
- 715 in postmenopausal women. Clin Infect Dis **2000**; 30(1): 152-6.
- 716 51. Hooton TM. Recurrent urinary tract infection in women. Int J Antimicrob 717 Agents **2001**; 17(4): 259-68.
- 718 52. Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated
- 719 treatment of uncomplicated recurrent urinary tract infections in young
- 720 women. Ann Intern Med **2001**; 135(1): 9-16.
- 721 53. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al.
- 722 Intercontinental emergence of *Escherichia coli* clone O25:H4-ST131
- 723 producing CTX-M-15. J Antimicrob Chemother **2008**; 61(2): 273-81.
- 724 54. Johnson JR, Thuras P, Johnston BD, et al. The Pandemic H30
- 725 Subclone of *Escherichia coli* Sequence Type 131 Is Associated With

- 729 55. Shevchenko SG, Radey M, Tchesnokova V, Kisiela D, Sokurenko EV. 730 *Escherichia coli* Clonobiome: Assessing the Strain Diversity in Feces 731 and Urine by Deep Amplicon Sequencing. Appl Environ Microbiol **2019**; 732 85(23).
- 733 56. Wirth T, Falush D, Lan R, et al. Sex and virulence in *Escherichia coli*: 734 an evolutionary perspective. Mol Microbiol **2006**; 60(5): 1136-51.
- 735 57. Tchesnokova V, Billig M, Chattopadhyay S, et al. Predictive

736 diagnostics for *Escherichia coli* infections based on the clonal

737 association of antimicrobial resistance and clinical outcome. J Clin

- 738 Microbiol **2013**; 51(9): 2991-9.
- 739 58. Roer L, Johannesen TB, Hansen F, et al. CHTyper, a Web Tool for
- 740 Subtyping of Extraintestinal Pathogenic *Escherichia coli* Based on the 741 fumC and fimH Alleles. J Clin Microbiol **2018**; 56(4).
- 742 59. Weissman SJ, Johnson JR, Tchesnokova V, et al. High-resolution two-743 locus clonal typing of extraintestinal pathogenic *Escherichia coli*. Appl 744 Environ Microbiol **2012**; 78(5): 1353-60.

757

758 **Table 1. Prevalence of different** *E. coli* **among women of different age**

760 a Prevalence of any or no *E. coli* carrying samples was calculated as percent from total number of samples; 761 prevalence of resistant *E. coli* carrying samples was calculated as percent of any *E. coli* carrying samples.

762 ^b P values were derived from logistic regression using age in years as predictor and *E. coli* carriage as 763 outcome, with sensitive/resistant *E. coli* carriage restricted for overall *E. coli* carriage in a sample; P < .05 764 in bold.

765

773 ^e P value calculated in Chi-square test comparing UTI in H30 or ST1193 vs any other *E. coli* carriers; P < 774 .05 in bold.

- 775 ^f P values calculated in logistic regression with age as a predictor, unconstrained or constrained by group
- 776 predictor; P < .05 in bold

777

778 **Table 3. Coincidence of sensitive and resistant** *E. coli* **in clinical urine samples with identified**

779 **uropathogen (N = 134) and respective fecal samples.**

780

- 781 ^aP value calculated in logistic regression of the outcome (uropathogen) from predictor (fecal *E. coli*)
- 782 b N/A, not applicable

783 **Table 4. Urinary** *E. coli* **prediction based on fecal** *E. coli* **sensitivity test results.**

785 a AUC, Receiving Operator Curve analysis (ROC) Area Under Curve

786

787 **Table 5. Predictive power of knowing fecal bacterial resistance for**

788 **treatment of UTI.**

789

Supporting information

- **S1 Fig.** Analysis of gut *E. coli* carriage and UTI incidence by age.
- **S2 Fig**. UTI incidence rates and uropathogens characteristics.
- **S3 Fig**. Phylogenetic relationship between fecal (F) and clinical urine (CU) *E.*
- *coli* belonging to the same clonal group but isolated from different patients.
- **S1 Table**. UTI *E. coli* resistant to antibiotics.
- **S2 Table**. Non- *E. coli* UTI uropathogens.
- **S3 Table**. All data by enrollee.